carbapenems has been researched along with aspirin in 1 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 48,947 | 6,817 | 13,778 |
Protein | Taxonomy | carbapenems (IC50) | aspirin (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
Integrin beta-3 | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
Integrin alpha-IIb | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Andini, R; Boccia, F; Corcione, A; De Rosa, R; Durante-Mangoni, E; Gagliardi, M; Karruli, A; Murino, P; Patauner, F; Ruocco, G; Sommese, P; Ursi, MP; Zampino, R | 1 |
1 other study(ies) available for carbapenems and aspirin
Article | Year |
---|---|
Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Aspirin; Carbapenems; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Resistance, Multiple, Bacterial; Female; Hospital Mortality; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Male; Middle Aged; Opportunistic Infections; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; SARS-CoV-2; Steroids; Survival Analysis; Treatment Outcome | 2021 |